TorreyPines gets NASDAQ notice; RHEI names new CEO;

> TorreyPines Therapeutics has received a deficiency notice from NASDAQ. TorreyPines release [1]

> RHEI Pharmaceuticals has named Dr. Geert Cauwenbergh as CEO. RHEI release [2]

> Memory Pharmaceuticals has garnered $2 million through the sale of about 4.7 million common shares. Memory Release [3]

> Codexis and India's Arch Pharmalabs announced a new strategic collaboration, expanding their three-year partnership in pharmaceuticals manufacturing. Codexis Release [4]

> Novosom has acquired a license from Isis Pharmaceuticals to access certain antisense inhibitors targeting CD40 mRNA for a number of indications. Novosom AG release [5]

> Anthera Pharmaceuticals has started a trial designed to gauge the efficacy of varespladib on known biological markers of cardiovascular risk. Report [6]

> A single injection of the hormone leptin proved sufficient to heal terminally ill mice sickened by type 1 diabetes. Report [7]

> Researchers have made great strides with denosumab using the information discovered by Amgen's Scott Simonet fourteen years ago. Report [8]

> New experiments at the University of Rochester determined that TNF alpha works through the Smurf1 enzyme, which turns off two proteins that spur bone development. And that insight is likely to play a role in the development of new RA drugs. Report [9]

> With Eli Lilly stacking up indications for Cymbalta, marketing the drug could get complicated. How to get the message across without confusing consumers about just what the product does? Report [10]

> Last week, the chief of the U.K.'s National Institute for Health and Clinical Excellence accused drug companies of overpricing their products. NICE seems to want a "central role in price negotiation" as the government is overhauling its Pharmaceutical Price Regulation Scheme. Report [11]

> The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the news of two cases [12] of the brain disorder progressive multifocal leukoencephalopathy, or PML, that emerged in late July. Report [13]

> The church-and-state separation of drugmakers and continuing medical education [14] continues apace. Now it's Stanford's medical school that's refusing to take industry funding for specific CME programs or courses. Report [15]

> If you ever doubt the growing black market for counterfeit prescription drugs [16], just check out this report from MarkMonitor, the brand-abuse tracking firm. Researchers found that the number of people visiting online pharmacy sites every day has tripled to 99,000 from 32,000 last year. Report [17]

And Finally... Boston-based Genzyme has joined a research consortium targeted at finding new ways to fight malaria. The biotech company is joining the Broad Institute of MIT and Harvard, the nonprofit Medicines for Malaria and India's Advinus Therapeutics to advance new drugs that target key enzymes responsible for the survival of the malaria parasite. Report [18]